Karuna Therapeutics
Latest round
- Series B
Last raised
- Apr 2019
Total raised
- $122M
Investors
- 10
About Karuna Therapeutics
, develops therapeutics for psychosis and cognitive disorders across the central nervous system (CNS) such as schizophrenia and Alzheimer's Disease. The company is advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected neurological conditions through the cultivation of deep expertise in neuroscience, and inventive thinking around drug discovery and development. Andrew Miller is the founder of the company.00 per share, under the ticker symbol NASDAQ: KRTX. The firm’s product KarXT targets the muscarinic acetylcholine receptors composed of xanomeline, a novel muscarinic acetylcholine receptor agonist (activator), and trospium chloride, a muscarinic receptor antagonist (blocker).4 million in revenue in 2020. The company plans to advance KarXT into a Phase 2 clinical trial for the treatment of dementia-related psychosis in the first half of 2022.
Who invested in Karuna Therapeutics
10 investors across 3 rounds
See all investors in Karuna Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Karuna Therapeutics
Who invested in Karuna Therapeutics?
Karuna Therapeutics has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Karuna Therapeutics raised?
Karuna Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Karuna Therapeutics last raise money?
Karuna Therapeutics's most recent round on record is a Series B, in Apr 2019.
What does Karuna Therapeutics do?
, develops therapeutics for psychosis and cognitive disorders across the central nervous system (CNS) such as schizophrenia and Alzheimer's Disease.
Where is Karuna Therapeutics headquartered?
Karuna Therapeutics is headquartered in Boston, US.
Which VCs invest in companies like Karuna Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Karuna Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Karuna Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.